Página 1 desde 30 resultados
Study design: A placebo-controlled adaptive multi-center randomized controlled trial.
Study population: High risk HCW with direct patient contacts, defined as physician assistants, respiratory therapists, nurses, physicians or other HCWs working at emergency rooms, ICUs and in locations within
In a 4-week crossover study in 38 patients with COPD, roflumilast 500μg daily significantly reduced sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Interestingly, the mechanism of anti-neutrophilic inflammation with roflumilast treatment in patients
This will be a prospective, randomized, blinded, placebo-controlled study to gather data on the effect of nitroglycerin on the pedal artery of patients with varying comorbidities. Patients will be divided into a treatment group and a control group. A detailed history will be taken from the patient
In 2014, the estimated population who were suffering from drug abuse and drug-related disorders reached over 29 million worldwide, making it a global health challenge. Moreover, 43.5 per million people die annually from associated drug use. According to the United Nations Office on Drugs and Crime
Cardiovascular Disease (CVD) is the primary non-communicable cause of global mortality killing more than 7 million people per year. Chronic inflammation plays a crucial role in the genesis of atherosclerosis which further leads to cardiovascular disease. Apical periodontitis is "an acute or chronic
Substantial evidence demonstrates sex and gender differences in the behavioral, biological, and clinical correlates of substance use disorders. Men tend to initiate use earlier and have higher lifetime prevalence rates of disorder, but women demonstrate more severe withdrawal, more rapid progression
The Substance Abuse and Mental Health Services Administration (SAMHSA) has made health care and health systems integration one of its main priorities to ensure that behavioral health is consistently incorporated within the context of health care delivery systems. However, this initiative has been
Globally, 1 in 3 adults or 1.2 billion people smoke. The World Health Organization (WHO) estimated that tobacco is responsible for the death of 1 in 10 adults worldwide, about 6 million premature deaths each year. In the United States (U.S.), cigarette smoking is responsible for more than 480,000
Background: Smoking is the main preventable cause worldwide of morbidity and premature death (1). It is a major and independent risk factor for coronary heart disease (CHD) (2). More than two-thirds of sudden cardiac death resulting from acute thrombus occurs in smokers (3). Compared to non-smokers
Background Postoperative ileus is a frequently occurring surgical complication. It is defined as temporary inhibition of propulsive bowel activity and is manifested by abdominal distention, nausea and vomiting and diet intolerance. It may lead to a prolonged hospital stay, hospital-acquired
Chronic obstructive pulmonary disease (COPD) is an illness with high morbidity and mortality in our society with a prevalence of about 10% of the population. Smoking represents the main risk factor for development of COPD having been associated with a greater decrease in lung capacity and increased
1. Scientific / historical background
Smoking is highly addictive and quitting is difficult. Relapse is common because of withdrawal symptoms such as craving, headache, mood change and irritation. In addition to pharmacotherapy, exercise can acutely reduce craving, withdrawal symptoms and negative
A dedicated team interviewed patients preoperatively and during the first five postoperative days and collected data regarding medical history, surgery, anaesthesia and the presence of postoperative headache by manual record review. The frequency of preoperative headache was assessed by asking the
Study subjects The study population consisted of subjects who were referred to the sleep unit of the Clínic Hospital, Barcelona, Spain, or the San Pedro de Alcantara Hospital, Cáceres, Spain, with a mild-moderate clinical suspicion of OSA or with notorious co-morbidity that induced frequent symptoms